Cargando…

Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension

Shigella is the second most deadly diarrheal disease among children under five years of age, after rotavirus, with high morbidity and mortality in developing countries. Currently, no vaccine is widely available, and the increasing levels of multidrug resistance make Shigella a high priority for vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Micoli, Francesca, Rossi, Omar, Conti, Valentino, Launay, Odile, Sciré, Antonella Silvia, Aruta, Maria Grazia, Nakakana, Usman Nasir, Marchetti, Elisa, Rappuoli, Rino, Saul, Allan, Martin, Laura B., Necchi, Francesca, Podda, Audino
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129577/
https://www.ncbi.nlm.nih.gov/pubmed/34017343
http://dx.doi.org/10.3389/fimmu.2021.671325
_version_ 1783694324503937024
author Micoli, Francesca
Rossi, Omar
Conti, Valentino
Launay, Odile
Sciré, Antonella Silvia
Aruta, Maria Grazia
Nakakana, Usman Nasir
Marchetti, Elisa
Rappuoli, Rino
Saul, Allan
Martin, Laura B.
Necchi, Francesca
Podda, Audino
author_facet Micoli, Francesca
Rossi, Omar
Conti, Valentino
Launay, Odile
Sciré, Antonella Silvia
Aruta, Maria Grazia
Nakakana, Usman Nasir
Marchetti, Elisa
Rappuoli, Rino
Saul, Allan
Martin, Laura B.
Necchi, Francesca
Podda, Audino
author_sort Micoli, Francesca
collection PubMed
description Shigella is the second most deadly diarrheal disease among children under five years of age, after rotavirus, with high morbidity and mortality in developing countries. Currently, no vaccine is widely available, and the increasing levels of multidrug resistance make Shigella a high priority for vaccine development. The single-component candidate vaccine against Shigella sonnei (1790GAHB), developed using the GMMA technology, contains the O antigen (OAg) portion of lipopolysaccharide (LPS) as active moiety. The vaccine was well tolerated and immunogenic in early-phase clinical trials. In a phase 1 placebo-controlled dose escalation trial in France (NCT02017899), three doses of five different vaccine formulations (0.06/1, 0.3/5, 1.5/25, 3/50, 6/100 µg of OAg/protein) were administered to healthy adults. In the phase 1 extension trial (NCT03089879), conducted 2–3 years following the parent study, primed individuals who had undetectable antibody levels before the primary series received a 1790GAHB booster dose (1.5/25 µg OAg/protein). Controls were unprimed participants immunized with one 1790GAHB dose. The current analysis assessed the functionality of sera collected from both studies using a high-throughput luminescence-based serum bactericidal activity (SBA) assay optimized for testing human sera. Antibodies with complement-mediated bactericidal activity were detected in vaccinees but not in placebo recipients. SBA titers increased with OAg dose, with a persistent response up to six months after the primary vaccination with at least 1.5/25 µg of OAg/protein. The booster dose induced a strong increase of SBA titers in most primed participants. Correlation between SBA titers and anti-S. sonnei LPS serum immunoglobulin G levels was observed. Results suggest that GMMA is a promising OAg delivery system for the generation of functional antibody responses and persistent immunological memory.
format Online
Article
Text
id pubmed-8129577
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81295772021-05-19 Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension Micoli, Francesca Rossi, Omar Conti, Valentino Launay, Odile Sciré, Antonella Silvia Aruta, Maria Grazia Nakakana, Usman Nasir Marchetti, Elisa Rappuoli, Rino Saul, Allan Martin, Laura B. Necchi, Francesca Podda, Audino Front Immunol Immunology Shigella is the second most deadly diarrheal disease among children under five years of age, after rotavirus, with high morbidity and mortality in developing countries. Currently, no vaccine is widely available, and the increasing levels of multidrug resistance make Shigella a high priority for vaccine development. The single-component candidate vaccine against Shigella sonnei (1790GAHB), developed using the GMMA technology, contains the O antigen (OAg) portion of lipopolysaccharide (LPS) as active moiety. The vaccine was well tolerated and immunogenic in early-phase clinical trials. In a phase 1 placebo-controlled dose escalation trial in France (NCT02017899), three doses of five different vaccine formulations (0.06/1, 0.3/5, 1.5/25, 3/50, 6/100 µg of OAg/protein) were administered to healthy adults. In the phase 1 extension trial (NCT03089879), conducted 2–3 years following the parent study, primed individuals who had undetectable antibody levels before the primary series received a 1790GAHB booster dose (1.5/25 µg OAg/protein). Controls were unprimed participants immunized with one 1790GAHB dose. The current analysis assessed the functionality of sera collected from both studies using a high-throughput luminescence-based serum bactericidal activity (SBA) assay optimized for testing human sera. Antibodies with complement-mediated bactericidal activity were detected in vaccinees but not in placebo recipients. SBA titers increased with OAg dose, with a persistent response up to six months after the primary vaccination with at least 1.5/25 µg of OAg/protein. The booster dose induced a strong increase of SBA titers in most primed participants. Correlation between SBA titers and anti-S. sonnei LPS serum immunoglobulin G levels was observed. Results suggest that GMMA is a promising OAg delivery system for the generation of functional antibody responses and persistent immunological memory. Frontiers Media S.A. 2021-05-04 /pmc/articles/PMC8129577/ /pubmed/34017343 http://dx.doi.org/10.3389/fimmu.2021.671325 Text en Copyright © 2021 Micoli, Rossi, Conti, Launay, Sciré, Aruta, Nakakana, Marchetti, Rappuoli, Saul, Martin, Necchi and Podda https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Micoli, Francesca
Rossi, Omar
Conti, Valentino
Launay, Odile
Sciré, Antonella Silvia
Aruta, Maria Grazia
Nakakana, Usman Nasir
Marchetti, Elisa
Rappuoli, Rino
Saul, Allan
Martin, Laura B.
Necchi, Francesca
Podda, Audino
Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title_full Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title_fullStr Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title_full_unstemmed Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title_short Antibodies Elicited by the Shigella sonnei GMMA Vaccine in Adults Trigger Complement-Mediated Serum Bactericidal Activity: Results From a Phase 1 Dose Escalation Trial Followed by a Booster Extension
title_sort antibodies elicited by the shigella sonnei gmma vaccine in adults trigger complement-mediated serum bactericidal activity: results from a phase 1 dose escalation trial followed by a booster extension
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129577/
https://www.ncbi.nlm.nih.gov/pubmed/34017343
http://dx.doi.org/10.3389/fimmu.2021.671325
work_keys_str_mv AT micolifrancesca antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT rossiomar antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT contivalentino antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT launayodile antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT scireantonellasilvia antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT arutamariagrazia antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT nakakanausmannasir antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT marchettielisa antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT rappuolirino antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT saulallan antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT martinlaurab antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT necchifrancesca antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension
AT poddaaudino antibodieselicitedbytheshigellasonneigmmavaccineinadultstriggercomplementmediatedserumbactericidalactivityresultsfromaphase1doseescalationtrialfollowedbyaboosterextension